Happel David 4
4 · Sagimet Biosciences Inc. · Filed Jul 20, 2023
Insider Transaction Report
Form 4
Happel David
DirectorPresident & CEO
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−1,011,826→ 0 totalExercise: $7.15Exp: 2032-10-16→ Common Stock (1,011,826 underlying) - Award
Stock Option (Right to Buy)
2023-07-18+1,011,826→ 1,011,826 totalExercise: $7.15Exp: 2032-10-16→ Series A Common Stock (1,011,826 underlying)
Footnotes (2)
- [F1]Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
- [F2]25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.